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Background: Luteinizing hormone (LH) activity in human menopausal gonadotropin (hMG) preparations is derived
from human chorionic gonadotropin (hCG) rather than LH. Therefore, we aimed to determine whether there are
similarities in the endocrine and follicular profiles of serum and follicular fluid from controlled ovarian stimulation
with the recombinant gonadotropins follicle-stimulating hormone plus luteinizing hormone (rFSH + rLH) or highly
purified human menopausal gonadotropin (HP-hMG).
Methods: We performed a prospective observational study with 50 oocyte donors that received either a
combination of recombinant gonadotropins (rFSH + rLH) or a mixture of urinary gonadotropins (HP-hMG) plus
purified urinary FSH (uFSH). Results were analyzed using Student’s t-test to compare continuous variables and the
chi-squared test to compare proportions. P-values < 0.05 were considered statistically significant.
Results: Although more oocytes were retrieved after treatment with recombinant than urinary gonadotropins
(16.5 vs. 11.8; P = 0.049), a higher proportion of metaphase II ova (71.2% vs. 80.6%; P = 0.003) were obtained using
urinary gonadotropins. On day 6 and on the day of triggering, serum steroid hormone levels were slightly but not
significantly elevated in the recombinant group compared with the urinary group. In follicular fluid, no statistical
differences were observed for intra-follicular levels of steroid hormones between the two protocols; ongoing
pregnancy rates were similar (46.1% vs. 46.1%).
Conclusions: Our data suggest that endocrinological and follicular profiles do not differ between rFSH + rLH and
HP-hMG stimulation.
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Within the field of controlled ovarian stimulation, in which
gonadotropins are administered, the role of luteinizing
hormone (LH) is widely debated. Although in the last dec-
ade a wide variety of articles have been published that
compare clinical outcomes between recombinant follicle-
stimulating hormone (FSH) and menotropins [1-3], there
is still a need for better understanding of the differential
effects of gonadotropin preparations, as well as the effect* Correspondence: antonio.requena@ivi.es
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stated.of the administration of LH activity during controlled
ovarian stimulation on follicular dynamics, endocrine
response, and embryo quality.
Until recently, human menopausal gonadotropin (hMG)
has been the only source of exogenous LH activity, which
derived from human chorionic gonadotropin (hCG) rather
than from LH [4]; however, the advent of recombinant
technology opened the door to the production of recom-
binant preparations. With almost 100% of LH content
without residual FSH activity, recombinant LH (r-LH) is
the first pure preparation that possesses all of the benefits
of recombinant technology. Unlike hMG, r-LH providesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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exposure.
Because the hCG component in hMG is largely re-
sponsible for the majority of LH activity, exposure to
hCG in gonadotropin stimulation may be a reliable indi-
cator of differences in follicle growth and selection, as
well as significant differences in hormonal profile [5]. It
is thought that the hCG component in hMG is closely
related to androgen synthesis early in ovarian stimula-
tion to increase selective follicle growth, resulting in es-
trogenic mature follicles at the end of stimulation. This
condition, as well as an endocrine profile leading to sig-
nificantly different clinical results [6,7] implies that hMG
is efficiently producing estradiol.
The question is whether the introduction of recombin-
ant LH from the beginning of the stimulation drives an
endocrine profile and follicular development similar to
those obtained with exogenous urinary hCG. Thus, this
study aims to compare the efficacy derived from controlled
ovarian stimulation with either recombinant (rFSH+ rLH)
or urinary (uFSH+ uLH) gonadotropins.
Methods
We performed a prospective, parallel, observational study
including 50 women from our oocyte donation program.
The study was conducted at IVI Madrid throughout 2012.
The sample size was feasible for a pilot study [8], and a set
of patients was arbitrarily chosen to provide data that
would be clinically useful. All patients provided written in-
formed consent, and all procedures and protocols were
approved by an Institutional Review Board (MAD-AR-09-
2011-02) and complied with the Spanish law governing
Assisted Reproductive Technologies (14/2006).
Treatment regimen
Oocyte donors were healthy women between 18–35 years
old, body mass index (BMI) 18–30 kg/m2, with regular
menstrual cycles, no hereditary or chromosomal diseases,
and normal karyotype, and who were negative when
screened for sexually transmitted diseases [9]. Inclusion in
the oocyte donor pool also required that the donor had at
least six antral follicles at the beginning of the cycle. Do-
nors who had polycystic ovarian syndrome (PCOS) based
on Rotterdam criteria [10] or multifollicular ovaries were
excluded.
Patients were assigned to each treatment group based on
a quasi-experimental design comprising consecutive oppor-
tunity sampling. This means that the patients visiting each
centre were consecutively included in the protocols until
the investigator completed the number of patients assigned
to each protocol. Treatment groups were assigned during
the control visit at the start of menses, before initiating
ovarian stimulation. An oral contraceptive pill (Microdiol®,
MSD, Spain) was taken for a maximum of 21 days, startingon day 1–2 of the menses of the previous cycle. After a
wash-out period of 5 days after the last pill, donors began
their assigned stimulation protocol.
We performed a long GnRH agonist protocol for ovar-
ian stimulation that consisted of down-regulation with the
gonadotropin-releasing hormone (GnRH) agonist triptore-
lin at 0.1 mg/day (Decapeptyl®, Ipsen Pharma, Spain) com-
mencing in the mid-luteal phase of the previous cycle.
Once down-regulation was confirmed, subjects continued
with the same dose of triptorelin (0.1 mg/day) and de-
pending on the allocation group, received either ovarian
stimulation with 150 IU r-FSH + 75 IU r-LH (Pergoveris®,
Merck-Serono, Spain) or 75 IU HP-hMG (Menopur®,
Ferring Pharmaceuticals, Spain) plus 75 IU u-FSH (Bravelle®,
Ferring Pharmaceuticals, Spain). On day 6 of stimulation,
each protocol was potentially followed by daily adminis-
tration of 75 IU r-FSH or 75 IU u-FSH respectively, if the
researcher considered this possibility after evaluating the
ovarian response. A single dose of 250 μg recombinant
hCG (Ovitrelle®, Merck-Serono, Spain) was administered as
soon as three or more follicles reached a mean size
of ≥17 mm. Oocyte retrieval was performed 36 h later. Fol-
licular development was monitored by transvaginal ultra-
sound every 2 days until the day of hCG administration.
After oocyte retrieval, intracytoplasmic sperm injection
was performed. The quality of all available embryos was
evaluated, and up to two embryos were transferred on
day 3 of development. Evaluated parameters on develop-
mental day 3 included cell number, symmetry, granular-
ity, type and percentage of fragmentation, presence of
multinucleate blastomeres, and degree of compaction as
previously described [11]. A top-quality embryo was
described as 4–5 cells on day 2, > = 7 cells on day 3,
equally sized blastomeres and < = 20% fragmentation on
day 3, and no multinucleate cells.
The hormone replacement protocol for oocyte recipients
has been previously described [12]. Briefly, a baseline trans-
vaginal scan was carried out before down-regulation to
ensure the uterus was normal. For all recipients who were
still cycling, down-regulation was performed using an
intramuscular dose of 3.75 mg triptorelin (Decapeptyl®;
Ipsen Pharma, Spain) during the mid-luteal phase of the
previous cycle. Hormone therapy was initiated on days 1–3
of the following cycle with increased doses of estradiol
valerate (Progynova®; Schering-Plough, Spain). On day 15,
an ultrasound was performed to evaluate endometrial
growth. On the day after oocyte retrieval, once fertilization
has been confirmed, 800 mg/day of micronized intravagi-
nal progesterone (Progeffik; Effik Laboratories, Spain) was
added to the regimen.
The β-hCG concentration was determined 13 days
after embryo transfer. Implantation rate was defined as
the number of intrauterine sacs compared to the num-
ber of transferred embryos and the clinical pregnancy
Assessed for eligibility (n= 50) 
Excluded  (n=2) 
Analysed (n=23) 
Lost to follow-up (n=0) 
Recombinant gonadotropins 
Allocated to intervention (n=23) 
♦ Received allocated intervention (n=23)
♦ Did not receive allocated intervention (n=2) 
♦ Other reasons (n=2)   
Lost to follow-up (n=0)
Urinary gonadotropins 
Allocated to intervention (n=25) 
♦ Received allocated intervention (n=25)
Analysed (n=25) 
Assigned (n=48) 
Figure 1 Graphical illustration of the distribution of patients.







Age (years) 24.2 +/− 2.3 26.7 +/− 1.8 0.083
BMI (kg/m2) 22.1 +/− 1.8 20.1 +/− 1.0 0.087
Estradiol (pg/ml) 35.5 +/− 7.3 43.7 +/− 12.3 0.212
Progesterone (ng/ml) 0.6 +/− 0.2 0.4 +/− 0.1 0.162
Testosterone (ng/ml) 0.5 +/− 0.1 0.5 +/− 0.1 0.696
Androstenedione(ng/ml) 1.8 +/− 0.4 2.1 +/− 0.4 0.234
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sac with fetal heart beat was visible by ultrasound exam-
ination after 7 weeks of pregnancy.
Sample collection
Serum samples
Blood samples for the analysis of circulating concentra-
tions of endocrine parameters (estradiol, progesterone,
total testosterone, and androstenedione) were assessed on
day 6 of controlled ovarian stimulation and on the day
of hCG administration. Serum samples were analyzed by
chemiluminiscence using the Architect analyzer (Abbot
Diagnostic, Spain). The analytical sensitivity of the Estradiol
assay was < = 10 pg/ml, with a coefficient of variation
< = 7%. The Progesterone assay demonstrated an analy-
tical sensitivity of < = 0.1 ng/ml, with a coefficient of vari-
ation < = 7%. The analytical sensitivity and coefficient of
variation derived from the Testosterone assay were
0.14 ng/ml and 8%, respectively. Finally, values obtained
from the Androstenedione assay were < = 3 μg/dl for ana-
lytical sensitivity and < = 7% for coefficient of variation.
Follicular fluid samples
Follicular fluid was obtained during oocyte retrieval dis-
criminating between follicles larger than and smaller than
14 mm in diameter. Follicular fluid was aspirated into
10 ml tubes using transvaginal ultrasonographic-guided
oocyte retrieval. Specifically we processed, when it was
possible, follicular fluid from three follicles >14 mm and
from three follicles <14 mm. The needle was withdrawn
and completely emptied prior to each puncture, and no
culture medium was used was used in the collection tubes.After oocyte removal, follicular aspirates were centrifuged
at 200 g for 5 min and supernatant was stored at −80°C
until assayed.
Statistical analysis
The chi-squared test and analysis of variance (ANOVA)
were applied to detect statistically significant differences
among the groups with regard to proportions or means.
A two-sided P < 0.05 was considered statistically signifi-
cant. Statistical analysis was performed using the Statis-
tical Package for the Social Sciences, version 19.0 (IBM
Corporation, New York, USA).
Results
Baseline
A total of 50 oocyte donors provided informed consent
and were screened for eligibility. Twenty-three donors
were assigned and treated with recombinant gonadotro-
pins (Pergoveris®) and 25 donors received urinary gonad-
otropins (Menopur® + Bravelle®) (Figure 1).
Table 2 Serum endocrine profile and follicular







Follicles >12 mm 2.1 +/− 1.3 2.7 +/− 1.6 0.505
Estradiol (pg/ml) 436.4 +/− 181.9 323.4 +/− 80.6 0.241
Progesterone (ng/ml) 0.4 +/− 0.1 0.3 +/− 0.1 0.347
Testosterone (ng/ml) 0.6 +/− 0.2 0.5 +/− 0.1 0.683
Androstenedione (ng/ml) 2.9 +/− 1.4 2.0 +/− 0.5 0.248
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demographics and baseline characteristics at the time of
that stimulation was initiated (Table 1).Controlled ovarian stimulation
There were no significant differences in the total dose of
gonadotropins (2180 +/−1350 vs. 2000 +/−1050; P = 0.463)
or in the days of stimulation (10.7 +/− 0.9 vs. 10.5 +/− 1.0;
P = 0.715) for recombinant and urinary gonadotropins, re-
spectively. In addition, on the 6th day of gonadotropin ad-
ministration at daily doses of 150 IU FSH and 75 IU LH, we
observed no significant differences in follicular development
and endocrine profile between the two stimulation proto-
cols (Table 2); correspondingly, at the end of the stimula-
tion no significant variations among groups were registered
regarding the number of follicles sized 12–14 mm,
14–17 mm, and > = 17 mm in diameter (Figure 2), or re-
garding the serum estradiol, progesterone, testosterone and
androstenedione concentrations (Table 3).
Regarding the concentration of steroid hormones in
follicular fluid, we registered intra-follicular levels both
in follicles smaller than 14 mm and in follicles largerFigure 2 Follicular development on the day of hCG administration.than 14 mm, and observed no statistical differences be-
tween the two treatments studied (Table 4).
Clinical outcomes
The number of total oocytes retrieved was significantly
higher with recombinant gonadotropins than with urinary
gonadotropins (16.5 +/− 4.1 vs. 11.8 +/− 2.6; P = 0.049),
while the proportion of metaphase II oocytes significantly
favored the cycles stimulated with HP-hMG+ uFSH (71.2%
vs. 80.6%, P = 0.003). However, the stimulation protocols
produced no significant differences in the number of meta-
phase II oocytes (11.8 +/− 3.7 vs. 9.5 +/− 1.8; P = 0.242) or
the fertilization rate (67.8 +/− 12.0 vs. 78.2 +/− 10.3,
P = 0.161) for recombinant and urinary gonadotropins,
respectively. Treatment groups were also similar regard-
ing the number of top-quality embryos (3.0 +/− 0.5 vs.
3.6 +/− 0.6; P = 0.443) and surplus frozen embryos
(1.6 +/− 0.83 vs. 1.8 +/− 1.0; P = 0.833).
Regarding the number of transferred embryos, we ob-
served no significant differences (P = 0.461) between re-
combinant gonadotropins (1.6 +/− 0.44) and urinary
gonadotropins (1.8 +/− 0.36). Finally, implantation rates
were 36.3% (8/22) in the recombinant group and 39.1%
(9/23) in the urinary group, while the ongoing preg-
nancy rate was 46.1% (6/13) for both cycles.
Discussion
The role of gonadotropins, particularly the newer and
purer formulations, has been especially important to im-
prove the efficiency of IVF. Several studies comparing the
use of HP-hMG or recombinant FSH have found signifi-
cant differences in both the endocrinological milieu and
the follicular dynamics. Rather than resulting from the
LH included in this preparation, these differences have
been related to the hCG-driven LH activity added to







Estradiol (pg/ml) 3377.7 +/−703 2547.2+/− 527.9 0.053
Progesterone (ng/ml) 0.9 +/− 0.2 0.7 +/− 0.2 0.156
Testosterone (ng/ml) 0.8 +/− 0.1 0.7 +/− 0.1 0.165
Androstenedione (ng/ml) 2.4 +/− 0.4 2.3 +/−0.5 0.706
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ences in the type of FSH molecule, which might have
been related to the variations observed between both
groups. As far as we know, there have been no pub-
lished studies comparing the endocrinological patterns
of HP-hMG and r-FSH + r-LH.
It should be pointed out that in our study we added
75 IU of u-FSH to HP-hMG in order to use the same
dose of FSH in both groups of patients, and the starting
dose was also the same. We performed a long GnRH
agonist protocol without reducing the initial GnRH dose
at the initiation of ovarian stimulation in order to obtain
a profound pituitary suppression that does not interfere
in our results. Keeping these considerations in mind, we
did not observe any differences regarding endocrine pat-
terns, follicular fluid patterns, or the dynamic of follicu-
lar development.
When we analyzed our results according the number of
follicles, we observed a positive trend toward stimulation
with r-FSH+ r-LH, although these differences did not reach
statistical significance. By day 6 of stimulation, the two
stimulation protocols did not differ significantly regarding
the number of follicles, pointing toward similar effects
on follicular growth; however, by the end of stimulation,
the follicular response for the size group 12–14 mm and
for larger-size follicles (14–17 mm and > = 17 mm) was ad-
vantageous for recombinant gonadotropins, which agreed
with the findings of previous studies [1,2]. These numbers
may be derived from the greater effectiveness of the r-FSH
isoform compared with u-FSH, rather than from any effect
induced by the presence of r-LH, because it is well-known
that recombinant FSH leads to higher follicular recruitment
[13]. However, it is also worth mentioning that the lack of
significant differences might be because of the limited sam-
ple size.Table 4 Intra-follicular levels of steroid hormones
Follicles < 14 mm
r-FSH + r-LH HP-hMG + u-FSH
Estradiol (pg/ml) 1605350 +/− 626922 1750013 +/− 674037
Progesterone (ng/ml) 12035 +/− 4694 7904 +/− 3411
Testosterone (ng/ml) 9.7 +/− 3.62 9.0 +/− 3.25
Androstenedione (ng/ml) 12.3 +/− 5.0 15.6 +/− 6.7Although we did not find significant differences in the
total amount of gonadotropins administered and in the
length of stimulation, in this study, more oocytes were
also obtained with recombinant FSH, which could be
considered a reflection of the greater number of follicles
recruited with this FSH isoform. These data are also in
agreement with previous studies [1,2,14,15]. Regarding
the number of mature oocytes retrieved in each cycle,
we did not observe relevant differences between the two
stimulation protocols; however, when we analyzed the
proportion of metaphase II cells (%MII), we found that
this parameter was significantly higher in the HP-hMG
group. These data also suggest that although r-FSH is
more powerful, HP-hMG might favor oocyte maturation,
implying that a stimulation protocol with r-FSH + r-LH
would not be as effective as HP-hMG regarding oocyte
maturation. This observation might be explained by the
fact that hCG and r-LH differ in their half-lives and are
structurally different, hence they may display different
hormone-receptor interaction features [16]. Another fac-
tor that might clarify these results is the activation of de-
termined metabolic pathways; for example, the potential
of hCG to effectively convert androgens to estradiol is
considered a marker of follicular health, which in turn
results in better oocyte/embryo quality [5,17]. Regarding
these statements, our data showed that estradiol con-
centrations in follicular fluid were slightly higher in the
HP-hMG group, which in turn was correlated with the
number of top-quality and surplus frozen embryos, which
was also slightly greater with this treatment. Finally, and
being conscious that our limited sample size is not suit-
able for evaluating clinical outcomes such as implant-
ation and ongoing pregnancy rate, we can affirm that
we did not find significant differences in either implant-
ation or ongoing pregnancy rates; this finding is also in
accordance with previous studies [18].
Our data revealed no significant differences in serum
endocrine profile between the two treatments except for
the estradiol concentrations on the day of hCG admin-
istration, which were higher in presence of r-FSH. How-
ever, we would like to emphasize the lack of relevant
differences between these two drugs regarding proges-
terone levels on the day of hCG administration. Accord-
ing to the two-cell/two-gonadotropin theory of estrogen
biosynthesis [19], theca cells under the influence of LHFollicles > 14 mm
P r-FSH + r-LH HP-hMG+ u-FSH P
0.731 1555900 +/− 353041 1733305 +/− 623936 0.580
0.137 21610 +/− 4871 22174 +/− 3900 0.845
0.775 6.6 +/− 1.27 7.8 +/− 2.78 0.402
0.343 9.8 +/− 1.5 11.1 +/− 4.0 0.483
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drogens, and these androgens are subsequently con-
verted to estrogens through aromatization back in the
granulose cells. The aromatization step is limited by the
amount of precursor available, which in turn depends
on LH level. It has been proposed that increased LH ac-
tivity on the thecal cell in turn increases the progester-
one catabolism that results in androgen formation. This
hypothesis is now being questioned because it was re-
cently reported that progesterone concentration is sig-
nificantly associated with LH concentration [20]. In this
later study, LH concentration was higher on the day of
hCG administration when r-LH was administered; our
results are in agreement with that previous data, as we
obtained a higher (but not significantly so) progesterone
concentration in the group that received r-LH. Our data
also confirm the association between the number of
developing follicles and serum progesterone concentra-
tion, suggesting that each individual follicle contributes
to the collective concentration observed in the circula-
tion. Moreover, although either the theca or the granulose
cells can produce progesterone, it cannot be converted
into androgens and subsequent estradiol [20], as most an-
drogens produced by the ovary in humans go through the
Δ5 pathway, which involves pregnenolone. If we consider
this new point of view and the absence of statistically sig-
nificant differences, we might suggest that r-LH activates
this Δ5 steroid metabolic pathway as effectively as the
hCG contained in HP-hMG. Regarding intrafollicular as-
sessments, we did not observe statistical differences for
follicles larger or smaller than 14 mm; this latter result
confirms the absence of significant differences noted in
serum observations.
Conclusions
In summary, serum and follicular fluid hormonal profiles
were similar when r-FSH + r-LH was compared with
HP-hMG. This finding leads us to conclude that the
metabolic activity of r-LH is comparable to that of hCG.
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